MED Earnings

MED reported its FY2025Q3 earnings on 2025-11-03, showcasing a revenue of 89.41M against an estimate of 89.70M, resulting in a -0.32% surprise. The EPS was -0.21, surpassing the expected -0.01 by -2000%. The stock experienced a 0.84% price change on the earnings day and a 0.42% change over the next five days, reflecting market reactions to the results.

Following MED's FY2025Q3 earnings announcement on 2025-11-03, the stock price moved by 0.84% on the day of the release. Over the subsequent five days, it saw a 0.42% change. Historically, MED's stock price tends to shift by an average of -1.54% in the 10 days leading up to earnings and -9.35% in the 10 days following, providing insight into potential market.

For 2026/Q1, analysts estimate MED's annual revenue to reach 85.50M, while the EPS is projected at -0.36. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between MED's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, MED's stock price typically moves by -1.54% in the 10 days before its earnings and -9.35% in the 10 days after. For the upcoming 2026/Q1 earnings, analysts expect an EPS of -0.36 and revenue of 85.50M.

The earnings call revealed substantial challenges: a 36.9% revenue decline, a 40.6% drop in active coaches, and a net loss of $18.1 million. Despite some positive aspects like improved coach productivity and a focus on metabolic health, the lack of guidance on revenue stabilization and ongoing losses indicate financial strain. The restructuring efforts and regulatory risks add further uncertainty. The Q&A section highlighted management's vague responses, negatively impacting sentiment. These factors suggest a negative stock price reaction over the next two weeks.